<DOC>
	<DOCNO>NCT00250744</DOCNO>
	<brief_summary>1 . To compare effectiveness gabapentin ( titrate to300mg TID day -2 5 ) aprepitant ( 125mg day 1 80mg day 2 3 ) control delay nausea vomit associate level 3 , 4 5 emetogenic chemotherapy patient experience delayed nausea and/or vomit first cycle chemotherapy . 2 . To evaluate compare safety profile associate anti-emetic regimen . 3 . To assess subject satisfaction anti-emetic therapy .</brief_summary>
	<brief_title>Comparison Aprepitant Versus Gabapentin Prevention Delayed Nausea Vomiting</brief_title>
	<detailed_description>The purpose study compare effectiveness aprepitant gabapentin treat `` delay '' ( day later ) nausea and/or vomit patient receive chemotherapy treatment cancer . Patients study receive aprepitant gabapentin addition standard medication use prevent nausea vomit . Aprepitant approve FDA nausea vomit . Gabapentin approve FDA treatment seizure may effective control nausea vomit due chemotherapy . Subjects receive aprepitant receive proven treatment delay nausea vomit , subject receive gabapentin receive drug show limited effectiveness . Patients eligible participation study go receive chemotherapy may cause nausea vomit . If patient delay nausea vomit first cycle treatment , offer chance receive additional treatment second cycle chemotherapy . The University New Mexico Health Sciences Center sponsor study . The first 40 patient enrol study participate pilot phase study . A pilot study small version full study determine effective treatment . All 40 patient pilot phase study come UNM . If pilot phase find successful , study continue approximately 200 patient eventually enrol . The full study conduct University New Mexico Cancer Research Treatment Center ( UNM CRTC ) , New Mexico VA Healthcare System , member New Mexico Cancer Care Alliance .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Male female patient , 18 year age old , eligible chemotherapy may participate trial follow criterion meet : 1 . Patients must diagnosis malignant disease schedule receive singleday intravenous chemotherapy drug combination drug consider elicit level 3 , 4 5 emesis ( appendix A ) . 2 . Males must surgically sterilize , agree practice adequate contraceptive precaution study . 3 . Females nonchildbearing potential ( i.e . surgically sterilize , least oneyear post menopausal ) may enter study . Females childbearing potential must negative pregnancy test ( urine serum hCG ) entry study , must agree practice adequate contraceptive precaution study . 4 . Written informed consent must obtain initiate protocol specify procedure . Patients follow eligible enrollment study . 1 . Any unstable medical disorder . 2 . Participation drug trial patient receive investigational drug within 30 day 5 halflives ( whichever longer ) precede screen phase study . 3 . Patients serum creatinine ≥ 2 dL/mL ; bilirubin ≥ 3 time ULN ; ECOG performance status ≥ 3 . 4 . Patients severe hepatic insufficiency evidence ascites , encephalopathy , coagulopathy , jaundice . 5 . Patients prescribed corticosteroid except replacement maintenance dose 10mg prednisone equivalent . Dexamethasone permit prophylactic component pre postchemotherapy antiemetic regimen define protocol . 6 . Primary secondary ( metastatic disease ) brain neoplasm : Signs symptom increase intracranial pressure Patients brain metastasis require treatment within 30 day entry study . Signs symptoms cerebral edema exclude patient entry study . Patients symptomatically `` silent '' metastasis may enrol study . 7 . Patients know hypersensitive gabapentin , neurokinin1 dopamine receptor antagonist , 5HT3 receptor antagonist , corticosteroid . 8 . Patients unwilling unable comply protocol . 9 . Patients exclude receive radiation therapy abdominal field ( T10L5 ) within 24 hour dose study medication give schedule receive radiation period assessment ( study day 02 arm A study day 06 arm B ) . Radiation field acceptable ( e.g . pelvic radiation , thoracic radiation ) . 10 . Patients nausea within one hour and/or emesis ( vomit and/or retch ) within 24 hour dose study medication . 11 . Patients take either gabapentin aprepitant within four week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>delay nausea vomit</keyword>
	<keyword>Emetogenic Chemotherapy</keyword>
	<keyword>Pilot Trial</keyword>
</DOC>